subcutaneous dosing comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-30. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
The Boer war was the beginning of types of conflict involving machine guns, shrapnel and observation balloons which were all used extensively in the First World War. Both sides used a scorched earth policy to deprive the marching enemy of food. And both had to corral civilians into makeshift huts by 'concentrating' them into camps. For example, at Buffelspoort, British soldiers were held in captivity in Boer encampments after surrendering their arms, and civilians were often mixed in with service personnel because the Boers did not have the resources to do otherwise. 116,000 women, children and Boer soldiers were confined to the Commonwealth concentration camps, of which at least 28,000 would die. The British saw their tactics of scorched earth and concentration camps as a legitimate way of depriving the Boer guerrillas of supplies and safe havens. The Boers saw them as a British attempt to coerce the Boers into surrender, with the camp inmates—mainly families of Boer fighters—seen as deliberately kept in poor conditions to encourage high death rates. Even in the 21st-century, the controversy around the British tactics continued to make headlines.
==== MeSH D12.125.740 – phosphoamino acids ==== MeSH D12.125.740.025 – 2-amino-5-phosphonovalerate MeSH D12.125.740.675 – phosphocreatine MeSH D12.125.740.700 – phosphoserine MeSH D12.125.740.725 – phosphothreonine MeSH D12.125.740.740 – phosphotyrosine
Fosdagrocorat (developmental code names PF-04171327 and PF-4171327; also known as dagrocorat 2-(dihydrogen phosphate)) is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM) which was under development for the treatment of rheumatoid arthritis but was never marketed. It is the C2 dihydrogen phosphate ester of dagrocorat, and acts as a prodrug of dagrocorat with improved pharmacokinetics. The drug reached phase II clinical trials prior to the discontinuation of its development.
Sources: en.wikipedia.org
The carbon exchange between atmospheric CO2 and carbonate at the ocean surface is also subject to fractionation, with 14C in the atmosphere more likely than 12C to dissolve in the ocean. The result is an overall increase in the 14C/12C ratio in the ocean of 1.5%, relative to the 14C/12C ratio in the atmosphere. This increase in 14C concentration almost exactly cancels out the decrease caused by the upwelling of water (containing old, and hence 14C-depleted, carbon) from the deep ocean, so that direct measurements of 14C radiation are similar to measurements for the rest of the biosphere. Correcting for isotopic fractionation, as is done for all radiocarbon dates to allow comparison between results from different parts of the biosphere, gives an apparent age of about 400 years for ocean surface water.
== Side effects == The main side effects of exenatide use are gastrointestinal in nature, including acid or sour stomach, belching, diarrhea, heartburn, indigestion, nausea, and vomiting. These tend to subside with time; exenatide is therefore not meant for people with severe gastrointestinal disease. Other side effects include dizziness, headache, and feeling jittery. Drug interactions listed on the package insert include delayed or reduced concentrations of lovastatin, paracetamol (acetaminophen), and digoxin, although this has not been proven to alter the effectiveness of these other medications. In response to postmarketing reports of acute pancreatitis in patients using exenatide, the US Food and Drug Administration (FDA) added a boxed warning to the labeling of Byetta in 2007. In August 2008, four additional deaths from pancreatitis in users of exenatide were reported to the FDA; while no definite relationship had been established, the FDA was reportedly considering additional changes to the drug's labeling. Examination of the medical records of the millions of patients part of the United Healthcare Insurance plans did not show any greater rate of pancreatitis among Byetta users than among diabetic patients on other medications. However, diabetics do have a slightly greater incidence of pancreatitis than do non-diabetics. It also may increase risk of mild sulfonylurea-induced hypoglycemia.
According to one cable, Deputy Assistant Secretary of State for European and Eurasian Affairs Matthew Bryza "has been clear with Saakashvili: if Georgia uses force or stumbles into a conflict, Saakashvili will find himself alone, blamed by the international community for recklessness." Tefft was told by an Abkhaz official in 2007 that there had been an attempt by Russia to coerce Abkhaz leader Sergei Bagapsh into launching a military operation against Georgia in 2006. President of France Nicolas Sarkozy assured Putin in October 2007 that France did not support Georgia's NATO membership while telling Saakashvili the opposite. In January 2008, the French government was not enthusiastic about Ukraine's plans to join NATO.
=== Liposomes structure === Liposomes are sphere-shaped vesicular structures self-assembled in a solvent composed of a broad type of lipids or other amphiphilic molecules. The vesicle structure of liposomes improves the effects on drug penetration through biological membranes, which enhance transdermal drug delivery.
Sources: en.wikipedia.org
Trump, who previously served as the 45th president of the United States from 2017 to 2021 and lost his reelection bid to Joe Biden in the 2020 presidential election, announced his candidacy for the nomination of the Republican Party in the 2024 presidential election on November 15, 2022. In March 2024, Trump secured the Republican nomination. Trump selected Senator JD Vance of Ohio, a former critic of his, as his running mate, and the two were officially nominated at the 2024 Republican National Convention. Early on November 6, 2024, the day after the election, Trump was projected to have secured the presidency. Trump won the presidential election with 312 electoral votes and 49.8% of the popular vote, while Kamala Harris received 226 electoral votes and 48.3% of the popular vote. Trump, upon taking office, became the second president in U.S. history to serve non-consecutive terms after Grover Cleveland in 1893, and the first with a felony to serve the presidency after his conviction in May 2024. In the concurrent congressional elections, Republicans secured a government trifecta after retaining their majority in the House of Representatives and winning back control of the Senate for the first time since his first presidency.
Postinflammatory hyperpigmentation (PIH) is a skin condition characterized by the darkening of the skin (hyperpigmentation) following an inflammatory injury, such as acne, dermatitis, infectious disease, or trauma. Less frequently, it may occur as a complication of a medical procedure performed on the skin. It is a common cause of skin discoloration and can affect individuals of all skin types.
As Smashburger began to grow, management brought in outside consultants in 2011 to develop a new program for music that would better fit a "modern, high-energy" restaurant concept, although it retains a family-friendly vibe. Music in restaurants was subsequently designed with a target audience of 32 years old, avoiding overly bubblegum or electronic music and rooted in contemporary pop, allowing its sound track to remain mainstream but allowing for older classics as well as new and emerging international music. International locations feature an American-inspired soundtrack as well. The company also has employee incentives for stores it owns directly which it credits with boosting morale, including paying $9 an hour in 2011, above the then-minimum wage of $7.25. Bonuses are awarded for certain milestones as well. Cooks are awarded extra money for filling orders in under six minutes, while managers are given bonuses for meeting monthly revenue goals and gaining positive customer reviews.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.